We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Intestinal perforation associated with rituximab therapy for post-transplant lymphoproliferative disorder after liver transplantation.
- Authors
Cornejo, Agustin; Bohnenblust, Mary; Harris, Catherine; Abrahamian, Gregory A
- Abstract
Post-transplant lymphoproliferative disorder (PTLD) is a serious complication after organ transplantation with a cumulative incidence of 1.1% at 18 months and 4.7% at 15 years. It has been reported in patients with or without concomitant Epstein-Barr virus infection. Therapy ranges from a reduction of immunosuppression to administration of conventional cytotoxic chemotherapy. Rituximab, a recombinant chimeric anti-CD20 monoclonal antibody has been used for the treatment of PTLD with promising results and a reduction in treatment-associated mortality. However, the use of rituximab has been associated with spontaneous gastrointestinal perforation. We describe a case of recurrent intestinal perforations after a single dose of rituximab.
- Publication
Cancer chemotherapy and pharmacology, 2009, Vol 64, Issue 4, p857
- ISSN
1432-0843
- Publication type
Journal Article
- DOI
10.1007/s00280-009-1062-1